Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Originally Published: 12/12/2025. 
Quick Look - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Rarely do speculative investors and patience go hand in hand. Nevertheless, if you’re looking to invest in the small-cap biotech sector, patience is essential. Most of these companies are still in the clinical stage, meaning they have no commercially available drugs or therapeutics. They typically have negative earnings (not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage drug or therapeutic. REVEALED: America just unlocked a $500 trillion asset
Everyone's talking about AI stocks but almost no one is talking about what AI actually runs on.
Nickel. Copper. Cobalt. Manganese.
America just secured exclusive rights to the largest untapped supply on Earth.
One company is already in position and this could be one of the most important AI infrastructure plays heading into 2026. The name and ticker are available here now >>> Even if a product advances through trials, profitability may still be years away. Only after reaching that milestone do companies usually gain the analyst coverage that attracts institutional investment. However, getting in on one of these medical stocks and having it pay off can be like winning the lottery. In an instant, investors could see 3x, 5x, or even 10x returns. Others may never pan out. That uncertainty is why many investors interested in penny stocks spread a lump sum equally across multiple biotech companies. If it is a numbers game, diversification can be an effective strategy. With that in mind, let's examine two small-cap biotech stocks that carry significant risks but also the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company specializing in epigenetics-based tests for the early detection of cancer. Unlike many penny stocks in the sector, Mainz Biomed has a commercial product: ColoAlert—the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, one of Germany’s leading pioneers in digital health. With more than 60,000 new colorectal cancer cases annually in Germany, the market opportunity is material. Mainz Biomed is also in the early stages of developing a non-invasive, blood-based screening test for early pancreatic cancer detection. The company reported positive topline results in October, but commercial approval is still years away. That said, the risks are substantial. ColoAlert is not yet available in the United States, and despite early sales in Europe and plans to expand into South America, revenue remains minimal. The company included “Going Concern” language in its Sept. 26 SEC filing. Since then, Mainz Biomed has filed a $150 million mixed shelf offering. For now, that has helped keep the MYNZ share price above $1 and avoid a delisting notice. The company is in a race to generate enough revenue to move the needle. If it succeeds, even a small investment could yield a sizable return. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech pursuing a potentially disruptive approach to antiviral treatment—but it also carries the financial risks speculative investors must weigh carefully. The company is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These drug candidates are designed to mimic human cell surfaces and lure viruses into binding with them, effectively neutralizing the pathogens before they can infect real cells. It’s an innovative concept that, if validated in human trials, could represent a fundamentally new method for infectious disease treatment. NanoViricides’ pipeline includes candidates targeting shingles (varicella-zoster virus), herpes simplex viruses (HSV-1 and HSV-2), and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has produced encouraging preclinical data suggesting potent antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and reliant on fresh capital to keep programs moving. Recent filings reported limited cash on hand, so investors should expect the possibility of future dilution. If one candidate advances into clinical development and validates the platform, valuation upside could be substantial. For patient investors with a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
